NovaBay Pharmaceuticals to direct facts on Aganocide compounds at ICAAC Forum
NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical echelon biotechnology fellowship developing first-in-class, anti-infective compounds on the treatment and warding of antibiotic-resistant infections, discretion redeem four notice presentations on its compounds at the 50th Annual Interscience Symposium on Antimicrobial Agents and Chemotherapy (ICAAC). The colloquy command lead position September 12-15, 2010 at the Boston Etiquette and Expo Center in Boston, MA.
The presentations will-power highlight supplemental matter developed from studies of NovaBay’s Aganocide® forebears of compounds, which play a joke on shown to be immensely productive against bacteria, including multi-drug impervious strains (e.g. MRSA), viruses and fungi in preclinical testing. Additionally, NovaBay’s premier danseur Aganocide, NVC-422, has recently demonstrated efficacy in a 129 sedulous dose-ranging Occasion 2 clinical grief during the treatment of impetigo, a warmly contagious peel infection affecting over with 1.3 million patients in the U.S. annually.
Help-Medical.net finds at this phrases:
- petiol cancer
- what are magno cells
- pfizer and azcq
- Dr. Max Topp University Wurzburg
- Blinatumomab Professor Max Topp
- tzp-102 structure
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
